SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Recruiting
Phase 1
Interventional Study
Human Papillomavirus Associated Carcinomas
Cervical Cancer
Head and Neck Cancers
Anal Cancer
Vulva Cancer
Vaginal Cancer
Penile Cancer
HPV-Related Malignancy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 18 (estimated)
- Sponsor
- The Affiliated Hospital of Qingdao University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
1. Greater than or equal to 18 years of age
2. HPV associated carcinomas
3. Patients must have at least one measurable lesion defined by RECIST 1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Key Exclusion Criteria:
1. Active or uncontrollable in…
Contacts